JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1^G2032R resistance mutation in NSCLC:...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Targeted therapies for ROS1-rearranged non-small cell lung cancer (NSCLC) are limited by resistance mutations, brain metastases, and central nervous system toxicities.
• Development of next-generation inhibitors is crucial to overcome these challenges and improve patient outcomes.

Purpose of the Study:

• To evaluate the safety, tolerability, and efficacy of JYP0322, a novel brain-penetrant ROS1 inhibitor, in patients with ROS1-fusion NSCLC.
• To assess JYP0322's ability to overcome resistance mutations, including ROS1^G2032R, and its activity in patients with brain metastases.

Main Methods:

• A Phase I clinical trial (NCT06128148) enrolled 89 NSCLC patients with ROS1-fusion.
• Preclinical studies assessed JYP0322's selectivity, antitumor activity, and brain penetration.
• Efficacy was evaluated based on objective response rate (ORR), including intracranial ORR in patients with brain metastases.

Main Results:

• JYP0322 demonstrated high selectivity for ROS1 over TRKA and potent antitumor activity in preclinical models.
• In the Phase I trial, JYP0322 was well-tolerated with low TRK-related neurologic events.
• High ORRs were observed in TKI-naive (95.7%), heavily pretreated (57.1%), and ROS1^G2032R-mutant (77.8%) patients.
• Intracranial ORR was 55.6% in patients with brain metastases.

Conclusions:

• JYP0322 is a safe and effective next-generation ROS1 inhibitor with significant activity in ROS1-fusion NSCLC.
• It demonstrates promising efficacy in heavily pretreated patients, those with brain metastases, and those harboring ROS1^G2032R resistance mutations.
• JYP0322 represents a potential new therapeutic option for advanced NSCLC patients with ROS1 alterations.